The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus (DISCLUP2008)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2008 by Florida Academic Dermatology Centers.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Florida Academic Dermatology Centers
Information provided by:
Florida Academic Dermatology Centers
ClinicalTrials.gov Identifier:
NCT00797784
First received: November 21, 2008
Last updated: May 25, 2010
Last verified: November 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A 20 week study to assess the safety and efficacy of etanercept(Enbrel®)for the treatment of Discoid Lupus Erythematosus
| Condition | Intervention | Phase |
|---|---|---|
|
Discoid Lupus Erythematosus (DLE) |
Drug: etanercept(Enbrel®) |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase 2 Open Label Study to Assess the Efficacy and Safety of Etanercept (Enbrel®)for the Treatment of Discoid Lupus Erythematosus |
Resource links provided by NLM:
Further study details as provided by Florida Academic Dermatology Centers:
Primary Outcome Measures:
- Proportion of patients responding to study treatment using the Cutaneous Lupus Erythematous Disease Area Severity Index(CLASI)defined as a decrease of 50% form baseline. [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Change from baseline to week 20 in Dermatology Life Quality Index and Pysician's Global Assessment of disease measurements [ Time Frame: 20 weeks ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 20 |
| Study Start Date: | October 2008 |
| Estimated Study Completion Date: | April 2011 |
| Estimated Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: etanercept(Enbrel®)
etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Subjects with discoid lupus erythematosus .Subjects require to have confirmation of diagnosis by a skin biopsy .This can be undertaken at the screening visit if no previous biopsy confirmation available.
And;
- Having failed steroids (topical, intralesional, systemic) and are candidates for antimalarial therapy
- Negative ANA
Have no history of latent or active TB prior to screening.
Exclusion Criteria:
- Subjects allergic to sunscreens
- Prior treatment with anti-TNF therapies
- Subjects who do not have a previous skin biopsy result confirming a DLE diagnosis and who are unwilling to undergo this procedure at screening.
- Subjects currently receiving systemic steroid therapy (or have received in the last 3 months)
- Known hypersensitivity to Enbrel® (etanercept) or any of its components or known to have antibodies to etanercept.
- Prior or concurrent use of cyclophosphamide therapy
- Concurrent sulfasalazine therapy.
- Known HIV-positive status or known history of any other immuno-suppressing disease.
- Any mycobacterial disease or high risk factors for tuberculosis (TB), such as family member with TB, positive purified protein derivative (PPD) or taking anti-tuberculosis medication
- Active or chronic infection within 4 weeks before screening visit, or between the screening and baseline visits.
- Severe comorbidities (diabetes mellitus requiring insulin; CHF of any severity; or myocardial infarction, cerebrovascular accident or transient ischemic attack within 6 months of screening visit; unstable angina pectoris; uncontrolled hypertension (sitting systolic BP <80 mm Hg or > 160 or diastolic BP > 100 mm Hg); oxygen-dependent severe pulmonary disease; history of cancer within 5 years [other than resected cutaneous basal or squamous cell carcinoma of the skin or in situ cervical cancer])
- Systemic lupus erythematosus, history of multiple sclerosis, transverse myelitis, optic neuritis or seizure disorder.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00797784
Contacts
| Contact: Annika M Grant, RN, MBA | 305 324 2110 ext 210 | annika@fadcenter.com |
Locations
| United States, Florida | |
| Florida Academic Dermatology Centers | Recruiting |
| Miami, Florida, United States, 33136 | |
| Contact: Annika M Grant, RN,MBA 305-324-2110 ext 210 annika@fadcenter.com | |
| Principal Investigator: Francisco A Kerdel, M.D. | |
Sponsors and Collaborators
Florida Academic Dermatology Centers
More Information
No publications provided
| Responsible Party: | Francisco A Kerdel,M.D., Florida Academic Dermatology Centers |
| ClinicalTrials.gov Identifier: | NCT00797784 History of Changes |
| Other Study ID Numbers: | FADC |
| Study First Received: | November 21, 2008 |
| Last Updated: | May 25, 2010 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Lupus Erythematosus, Discoid Lupus Erythematosus, Systemic Lupus Erythematosus, Cutaneous Connective Tissue Diseases Skin Diseases Autoimmune Diseases Immune System Diseases TNFR-Fc fusion protein Immunoglobulin G Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Gastrointestinal Agents Immunologic Factors Immunosuppressive Agents Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 22, 2013